Catalio Capital Management’s Definium Therapeutics DFTX Stock Holding History
Bought
Maintained
Sold
Other funds holding DFTX
Catalio Capital Management's DFTX Position: Q3 2026 in Review
Catalio Capital Management reduced its Definium Therapeutics (DFTX) stake by 12% in Q3 2026, selling an estimated $2.73M and leaving 497,964 shares worth $19M. The position accounts for 3.52% of the portfolio, ranked #9.
Catalio Capital Management first reported a position in DFTX in Q1 2026 and has held it in 3 quarters since. The position peaked at $26.5M in Q2 2026. 354 funds tracked by Wall St. Rank hold DFTX as of Q3 2026.
- Catalio Capital Management held 497,964 shares of Definium Therapeutics worth $19M as of Q3 2026.
- Catalio Capital Management sold 64,708 Definium Therapeutics shares in Q3 2026, an estimated $2.73M.
- Definium Therapeutics made up 3.52% of Catalio Capital Management's portfolio in Q3 2026, its #9 holding.
- Catalio Capital Management first reported a position in Definium Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Catalio Capital Management's Definium Therapeutics position peaked at $26.5M in Q2 2026.
- 354 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2026.
Based on Catalio Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.